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Abstract. Indoleamine 2,3-dioxygenase (IDO)-induced 
immunosuppression can be clinically beneficial for auto-
immune diseases. Primary biliary cirrhosis (PBC) is 
characterized by autoimmune lesions of intrahepatic bile 
duct epithelial cells that may lead to irreversible cirrhosis 
or hepatocellular carcinoma. The present study assessed the 
expression and function of IDO in a cell culture model and 
in PBC patients. IDO expression was monitored in a human 
immortalized but non-malignant biliary epithelial cell (iBEC) 
line. Increased expression of IDO1/2 was observed in the 
iBECs following stimulation with interferon-γ (IFN-γ). The 
induction of IDO was IFN-γ-dependent, but was indepen-
dent of the transforming growth factor-β (TGF-β) pathway. 
IDO enzymatic activity was observed in the supernatant of 
iBECs following stimulation with IFN-γ using colorimetric 
assays. A total of 47 serum samples from PBC patients were 
used to examine IDO activity by high-performance liquid 
chromatography, with samples from 24 healthy volunteers 
used as controls. Patients with PBC exhibited an increased 
rate of tryptophan to kynurenine conversion (P>0.01). Liver 
sections from patients with PBC (n=5) and those of healthy 
controls (n=5) were used for immunohistochemical studies. 
IDO expression was observed in biliary epithelial cells and in 
hepatocytes of PBC patients. Finally, the effect of tryptophan 
metabolites on human cluster of differentiation (CD) 4+ T cells 
in inducing polarization towards a regulatory T cell phenotype 
was examined. 3‑Hydroxykynurenine significantly upregu-
lated the fraction of CD4+ cells expressing forkhead box p3 
(Foxp3). The results of the present study suggest a therapeutic 
opportunity for the management of PBC and indicate that 
tryptophan catabolism could serve as a potential biomarker to 
monitor disease progression.
Introduction
Indoleamine 2,3-dioxygenase (IDO) is an intracellular enzyme 
that acts as an immunosuppressant (1). IDO serves a crucial 
role in the induction of tolerance during infection, cancer 
and autoimmune diseases (2,3). IDO expression is induced 
by interferon-γ (IFN-γ) during inflammation (4). The IDO 
pathway includes two related but distinct enzymes encoded by 
genes IDO-1 and IDO-2 (5). The two IDO enzymes may have 
a differential range of expression and signaling pathways, and 
differ in their selectivity for certain inhibitors (6,7). However, 
their specific contribution to immune regulation is not fully 
understood.
Primary biliary cirrhosis (PBC) is an inflammatory auto-
immune disease that targets the biliary epithelial cells (BEC) 
in the liver. Impaired IDO generation contributes to the prog-
ress of autoimmunity in PBC (8). Defects in the regulatory cell 
niche are vital to the advancement of autoimmunity, but PBC is 
characterized by a quantitative decline in the cluster of differ-
entiation (CD)4+CD25+ forkhead box p3 (Foxp3+) lymphocyte 
[regulatory T-cell (T-reg)] compartment that may be a key 
point in the pathogenesis of disease (9). It has been speculated 
that the destruction of the biliary tract in PBC is mediated by 
auto-reactive CD4+, as well as CD8+ T cells (10,11).
Overexpression of IDO may induce immunosuppression 
and tolerance; this has been established following studies in 
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multiple animal models (1,12,13). IDO has been shown to 
modulate immune response in two ways. Firstly, it depletes tryp-
tophan, which produces a cellular stress reaction through the 
general control non-repressed 2 (GCN2) kinase pathway (14), 
leading to the production of tryptophan metabolites (15). These 
metabolites contribute to the immunosuppressive effects 
of IDO by inhibiting T-cell responses (16). Secondly, IDO 
induces immunosuppression by producing kynurenine (Kyn), 
a ligand for the aryl hydrocarbon receptor (15); this promotes 
differentiation of Foxp3+ T-regs and decreases the immunoge-
nicity of dendritic cells (DCs) (12,13). It has been established 
that human T cells are responsive to the anti-proliferative and 
cytotoxic effects of supplemented Kyns (16,17). Kyns suppress 
proliferation and have pro-apoptotic properties, primarily 
in T-helper (Th) 1 lymphocytes, which respond to antigen 
presentation (18,19). The mechanisms by which tryptophan 
metabolites affect T cells are presently ambiguous; they may 
have direct toxic effects or could bind to the receptor that 
induces T-cell death (20).
The mutual outcome of tryptophan deprivation and 
increased Kyn concentration depends on the GCN2 
kinase-mediated downregulation of the TCRζ-chain in CD8+ 
cells, reducing their cytotoxic effects (21). Furthermore, the 
depletion of tryptophan, together with the increased genera-
tion of tryptophan metabolites, polarizes the differentiation of 
naïve CD4+CD25- T cells towards a regulatory phenotype (21).
IDO is upregulated by certain cytokines and inflammatory 
molecules; however, its most potent stimulator is IFN-γ (4). 
Transforming growth factor-β (TGF-β) serves a pivotal role 
in establishing tolerance and preventing autoimmunity (22). 
IDO is an essential intermediary that links TGF-β produc-
tion by DCs with T-reg differentiation and the induction of 
tolerance (23). TGF-β (24), IL-10 (25) and nitric oxide (26) 
are negative regulators of IDO. With the exception of IL-10, 
expression of these regulators in the liver of PBC patients is 
increased (27,28).
In the present study, we hypothesized that IDO may have 
a potential role in the pathogenesis of human PBC. High IDO 
activity in the biliary epithelial H69 cell line may offer an 
insight into the role of IDO in the pathogenesis of PBC. Thus, 
the following were investigated: i) The functional enzymatic 
activity of IDO in the cell line and serum samples of PBC 
patients and controls; ii) the expression of IDO in control and 
PBC liver tissues; and iii) whether Kyns modulate the human 
CD4+ T cells polarization toward a T-reg phenotype.
Materials and methods
Patients. The present study was conducted with local regional 
ethics committee approval, and written informed consent 
for publication of this study was obtained from all patients. 
Samples included serum collected for the purposes of research 
and excess liver biopsy tissue from diagnostic procedures. The 
mean age of patients was 58 years, with an age range between 
35 and 66 years. All samples were anonymized. To discount 
the variable effects due to gender difference, all patients with 
PBC and all healthy controls included in the study were female.
Cell culture. The H69 immortalized biliary epithelial cell 
(iBEC) line was created and obtained from Grubman et al (29) 
(Tufts University School of Medicine, Boston, MA, USA) 
from human intrahepatic biliary epithelial cells and was used 
for the current study. These cells exhibit characteristics of 
normal human biliary epithelium, with expression of cyto-
keratin (CK)7 and 19. The iBECs were cultured in 75-cm2 
flasks, at 37˚C in an atmosphere containing 5% CO2, in a 3:1 
mix of Dulbecco's modified Eagle's medium and Nutrient 
Mixture F12 Ham (Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany) supplemented with 1.8x10-4 M adenine (24.3 mg/l), 
2x10-9 M triiodothyronine (1.345 µg/l), 5.5x10-6 M epinephrine 
(1.0 mg/l) (all from Sigma-Aldrich; Merck KGaA), ITS-X 
supplement (10 mg/l insulin, 5.5 g/l transferrin, 2.0 g/l etha-
nolamine and 6.7 µg/l sodium selenite; Gibco; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA), 1 µM hydrocortisone 
solution (362.46 µg/l), 10% heat‑inactivated fetal bovine 
serum and 100 U/ml each of penicillin and streptomycin (all 
from Sigma-Aldrich; Merck KGaA).
H69 cells treated with IFN‑γ. H69 cells were treated with 
20 ng/ml IFN-γ. Once confluent (>80%), the cells were then 
left post- IFN-γ treatment for 0, 6, 12, 24, 48, 72, 96 and 120 h 
prior to RNA isolation or harvesting of supernatants.
H69 cells treated with TGF‑β type‑1 receptor serine/threonine 
kinase (ALK5) inhibitor. H69 cells were incubated with an 
ALK5 inhibitor (SB-505124; catalog no. 3263; TOCRIS 
Bioscience, Bristol, UK) at an optimal concentration of 
1 µΜ (30) for 1 h prior to stimulation with IFN-γ for 6 and 24 h.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). RNA isolation was performed according to the 
method developed by Chomczynski and Sacchi (31). TRIzol 
reagent (Sigma-Aldrich; Merck KGaA) was used according 
to the manufacturer's instructions. RNA was quantified 
and quality-assessed using a NanoDrop spectrophotometer 
(NanoDrop ND‑1000; Thermo Fisher Scientific, Logan, UT, 
USA). Isolated RNA was reverse transcribed to cDNA using 
the AffinityScript Multi Temperature cDNA Synthesis kit 
(Agilent Technologies, Inc., Santa Clara, CA, USA) according 
to the manufacturer's protocol. The qPCR experiments in 
this project utilized TaqMan chemistry and were performed 
in a MicroAmp Optical 96-well plate (both from Applied 
Biosystems; Thermo Fisher Scientific, Inc.) on a StepOnePlus 
Real-Time PCR machine (Applied Biosystems; Thermo 
Fisher Scientific, Inc.), with each well containing 1 µl TaqMan 
primer-probe (all primers were exon-spanning), 1 µl cDNA, 
10 µl Master Mix and 8 µl RNase-free water. Primers used 
were for GAPDH (catalog no. Hs02758991_g1), IDO-1 (catalog 
no. Hs00984148_m1), IDO-2 (catalog no. Hs01589373_m1), 
TGF-β1 (catalog no. Hs00998133_m1), TGF-β2 (catalog 
no. Hs00234244_m1) and were all purchased from Applied 
Biosystems; Thermo Fisher Scientific, Inc. The thermocycling 
conditions were as follows: 50˚C for 1 min, 95˚C for 10 min, 
followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min. 
Data were normalized to the expression of GAPDH mRNA 
using the 2-ΔΔCq method (32) and analyzed using REST 2009 
software (Qiagen GmbH, Hilden, Germany).
Immunohistochemistry. Formalin‑fixed, paraffin‑embedded 
liver biopsy sections from patients were deparaffinized in 
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xylene and rehydrated. Antigen retrieval was conducted 
by pressure‑cooking (pressure, 15PSI; temperature, 121˚C) 
for 1 min in Tris/EDTA (pH 8.0). To block endogenous 
peroxidase activity, 3% H2O2 in methanol was utilized and a 
biotin block was performed according to the manufacturer's 
protocol (Avidin/Biotin Blocking kit; catalog no. SP-2001; 
Vector Laboratories, Ltd., Peterborough, UK). Sections were 
incubated either with anti-IDO antibody (catalog no. ab55305; 
dilution, 1:100) or anti-Foxp3 antibody (catalog no. ab20034; 
dilution, 1:100) (both from Abcam, Cambridge, UK) in normal 
swine serum at 4˚C, in a humidified chamber overnight. 
Following washing with 0.1% Tween‑20 in PBS, sections were 
incubated with biotinylated anti-mouse secondary antibody 
(catalog no. BA-9200; dilution, 1:200; Vector Laboratories, 
Ltd.) for 1 h at room temperature in a humidified chamber. 
Sections were then stained with Vectastain peroxidase ABC 
kit (Vector Laboratories, Ltd.), according to the manufacturer's 
protocol. Staining was developed with 3,3'-diaminobenzidine 
(Sigma-Aldrich; Merck KGaA) and counterstained with 
Mayer's hematoxylin (Dako; Aglient Technologies, Inc.), 
according to the manufacturers' protocols. Sections stained 
with no primary antibody was used as a negative control. 
Visualization was performed using an optical microscope 
(Provis AX-70; Olympus Corporation, Tokyo, Japan).
High‑performance liquid chromatography (HPLC). HPLC 
was performed on a Shimadzu LC-10ADVP system (Shimadzu 
Corporation, Kyoto, Japan). The separation was performed 
isocratically using a Cronusil-S ODS1 (250x4.6-mm) column 
(SMI‑LabHut, Ltd., Gloucester, UK) at 25˚C at a flow rate of 
1 ml/min. The mobile phase contained 15 mM sodium acetate 
(pH 5.0) and acetonitrile [94:6% (v/v)]. Following injection 
(25 µl), the eluted Kyn was monitored at 360 nm between 0 
and 8.5 min, and after 8.5 min, tryptophan was monitored at 
278 nm. A working-top standard solution containing 10 µM 
Kyn and 100 µM tryptophan was made in mobile phase and 
further diluted to create a standard curve. Standard or sample 
(200 µl) was mixed with 50 µl sulfosalicylic acid, incubated 
on ice for 15 min and clarified by centrifugation for 15 min 
at 18,000 x g at 4˚C. Supernatant (25 µl) was injected into the 
HPLC system. Kyn typically eluted at ~6.5 min and tryptophan 
at 9.4 min. Standard curve and sample quantification was based 
on peak area using LCSolution software (version 1.11SP1; 
Shimadzu Corporation).
Colorimetric assay. Kyn was measured spectrophoto-
metrically, as described previously (33). A total of 75 µl 30% 
trichloroacetic acid was added to 100 µl of the culture super-
natant, vortexed and centrifuged at 10,000 x g for 5 min at 4˚C. 
Following this, a 75-µl volume of the supernatant was then 
added to an equal volume of Ehrlich's reagent (100 mg dimeth-
ylbenzaldehyde and 5 ml glacial acetic acid) in a microtiter 
plate well. Optical density was measured at 492-nm using a 
Multiskan MS microplate reader (Thermo Labsystems, Santa 
Rosa, CA, USA). A standard curve of defined Kyn concentra-
tion (0-100 µM) permitted analysis of unknowns.
Tryptophan metabolites. 3-Hydroxykynurenine (3-HK), 
Kyn and 3-hydroxyanthranilic acid (3-HAA) (all from 
Sigma-Aldrich; Merck KGaA) were dissolved in RPMI-1640 
medium and added to CD4+ T cells in culture at concentrations 
between 0 and 100 µM (pH 7.5-8.5).
Isolation of human CD4+ T‑cells. Isolation of human 
CD4+ T cells was performed using Rosette Sep (Stemcell 
Technologies, Vancouver, BC, Canada) human CD4+ T-cell 
enrichment cocktail at 50 µl/ml of whole blood (500 µl/10 ml), 
according to the manufacturer's protocol. Briefly, the whole 
blood was taken from a healthy donor and incubated with the 
cocktail for 20 min at room temperature. The sample was 
diluted with an equal volume of PBS (plus 2% FBS) and mixed 
gently. This was layered on top of the density medium and 
centrifuged at 1,200 x g for 20 min at room temperature. The 
enriched cells were isolated from the density medium-plasma 
interface and washed with PBS with 2% FBS. Isolated CD4+ T 
cells (1x105 cells/well) were stimulated with anti-human CD3 
and CD28 beads at the ratio of one bead per cell (Dynabeads 
Human T‑activator; Invitrogen; Thermo Fisher Scientific, Inc.) 
in the presence of tryptophan metabolites, 3-HK, 3-HAA and 
L‑Kyn (Sigma‑Aldrich; Merck KGaA) at 50 µΜ concentration, 
with 10 ng/ml TGF-β1 (R&D Systems Europe, Ltd., Abingdon, 
UK) used as a control; cells were incubated for 5 days.
Intracellular staining of T‑regulatory cells. Intracellular 
staining for Foxp3 was performed using a Foxp3 intracellular 
staining kit (eBioscience; Thermo Fisher Scientific, Inc.), 
according to the manufacturer's protocol. This kit has been 
formulated and optimized to stain intracellular antigen Foxp3 
(clone: PCH101; allophycocyanin, catalog no. 17-4776-42; 
eBioscience™, Invitrogen; Thermo Fisher Scientific, Inc.). 
Cells were stained for intracellular staining. Briefly, cells 
suspended in FACS tubes were pelleted by centrifugation at 
500 x g for 5 min at 4˚C. Following removal of the super-
natant, cells were fixed in a fixation/permeabilization buffer 
(1‑part fixation/permeabilization concentrate to 3 parts fixa-
tion/permeabilization diluent) for 30 min at 4˚C. Cells were 
then washed and centrifuged in permeabilization buffer at 
500 x g for 5 min (at 4˚C) followed by 1‑h incubation with 
the primary antibody. Finally, cells were washed twice in 
permeabilization buffer prior to re-suspension in FACS buffer 
(PBS with 2% FBS) and analyzed using a FACSCanto II flow 
cytometer and BD FACSDiva™ software, version 7.0 (both 
from BD Biosciences, Franklin Lakes, NJ, USA).
Statistical analysis. Statistical analysis was performed using 
GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, 
USA). Unless otherwise noted, data represent the mean value 
of an experiment conducted in triplicate ± standard error 
of the mean. For comparison between 2 groups, unpaired 
two-tailed Student's t-tests or Mann Whitney unpaired t-test 
were performed. For ≥3 groups, a one‑way analysis of vari-
ance test was performed and, if significant, a post‑hoc Tukey's 
analysis was performed. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Expression of IDO in iBECs. A prior study established an 
in vitro model using iBECs to investigate the link between 
senescence and epithelial cell de-differentiation (30). The 
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present study assessed the expression of mRNA encoding 
IDO-1, IDO-2, TGF-β1 and TGF-β2 following stimulation of 
iBEC with IFN-γ, for 6 and 24 h. Fig. 1 demonstrates the signifi-
cant increase (P<0.05) in the expression of IDO-1 (6,644-fold) 
with IFN-γ at 6 h. The results shown were normalized against 
the housekeeping gene GAPDH. High levels of IDO-1 expres-
sion were sustained at 24 h in IFN-γ treated cells; whereas no 
detectable expression of IDO-1 was found in untreated iBECs 
(data not shown).
Increase in IDO-2 expression was observed in cells 
treated with IFN-γ (P<0.01). Expression of TGF-β2 was also 
upregulated (12-fold) upon treatment with IFN-γ at 6 h, but 
expression was reduced at 24 h. There was no significant 
increase in expression of TGF-β1 following stimulation 
with IFN-γ; however, TGF-β2 expression was significantly 
increased.
To determine whether IDO-1 expression is dependent on 
the TGF-β pathway, cells were incubated with an ALK5 inhib-
itor (SB‑505124) at an optimal concentration of 1 µΜ (30) for 
1 h prior to stimulation with IFN-γ for 6 and 24 h. The expres-
sion of IDO‑1 was not significantly different in the treated or 
the untreated group (P>0.05, data not shown). These findings 
suggest that IDO-1 expression in iBEC is inducible, with a 
marked increase following IFN-γ stimulation, but independent 
of the TGF-β pathway.
Enzymatic activity of IDO is upregulated by IFN‑γ 
stimulation in iBECs. Certain studies have revealed an incon-
sistency between the expression of IDO and its enzymatic 
activity (34,35); thus, the present study examined the enzy-
matic activity of IDO in iBECs. A colorimetric assay was used 
to measure the levels of Kyn in the culture supernatant (Fig. 2). 
Figure 1. Quantification of IDO‑1/2 and TGF‑β1/2 mRNA in immortalized biliary epithelial cells. Cells were treated with IFN-γ (20 ng/ml) for 6 and 24 h. 
RNA was extracted and cDNA was prepared. mRNA for target genes was normalized to GAPDH and compared to unstimulated cells using quantitative 
polymerase chain reaction analysis. Data are presented as the mean of the results of three individual experiments; error bars indicate standard deviation. 
***P<0.05 vs. 6 h IFN, **P<0.05 vs. 6 h IFN, *P<0.01 vs. 6 h IFN. IDO, indoleamine 2,3-dioxygenase; TGF-β, transforming growth factor-β; IFN-γ, interferon-γ.
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Cells were stimulated with IFN-γ for up to 120 h. The superna-
tant of unstimulated iBEC produced no Kyn. The difference in 
Kyn levels between the IFN-γ-stimulated and the unstimulated 
iBECs was significant (P<0.05).
IDO activity in PBC patient sera. IDO activity was measured 
by assessing the ratio of the enzyme substrate tryptophan and 
its product Kyn (Fig. 3). Higher IDO activity was observed in 
the sera of PBC patients (n=47) compared with the healthy 
controls (n=24). Statistically significant differences were 
found between the two groups when measuring the area and 
height of peaks as determined by HPLC (Fig. 3).
Expression of IDO in BECs from the patients with PBC. To 
assess IDO expression in PBC, an immunohistochemical 
assay was performed. Expression of IDO in the liver tissue 
was examined in samples from healthy controls (n=5) and 
patients with PBC (n=5). No expression was observed in 
the cholangiocytes of healthy controls (Fig. 4A). Fig. 4B-D 
reveals IDO expression in late-stage PBC. Discrete staining is 
revealed in the BECs (Fig. 4B). IDO expression was increased 
in periportal hepatocytes, in conjunction with notable inter-
face hepatitis (Fig. 4C and D). Sections from matched PBC 
patients stained for Foxp3 are presented in Fig. 4E and F; 
Foxp3+ cells were morphologically small lymphocytes. There 
was an evident increase in the number of inflammatory cells, 
particularly those with interface hepatitis and IDO expression.
Tryptophan metabolites induce the T‑reg phenotype from 
the whole human CD4+ T cell population. IDO may induce 
T-regs, at least in part, through certain tryptophan metabo-
lites. To test this, human CD4+ T cells were stimulated with 
anti-CD3/CD28 beads in the presence of 50 µM of the Kyns, 
L-Kyn, 3-HK and 3-HAA for 5 days. T-reg development was 
assessed by analyzing Foxp3 expression with flow cytometry.
There was no significant difference in the proportion of 
CD4+ cells expressing Foxp3 in the presence of L-Kyn and 
3-HAA compared with the control after 5 days (Fig. 5); 
however, 3‑HK was significantly upregulated in the fraction of 
CD4+ cells expressing Foxp3.
Discussion
To the best of our knowledge, the current study establishes 
the expression of IDO in H69 iBECs for the first time, and 
reveals the increased rate of conversion of tryptophan to Kyn 
in patients with PBC. Furthermore, clinical biopsies from 
PBC patients demonstrated that the expression of IDO was 
observed not only in BECs, as described previously (8), but 
also in hepatocytes.
The transcriptional profile of IDO in iBECs was assessed 
following direct stimulation with IFN-γ, and levels were found 
to be significantly increased. IFN‑γ induced IDO expression 
in the iBECs. This suggests that the expression of IDO in 
iBECs is highly responsive to IFN-γ stimulation. Data from 
the present study is in agreement with earlier studies, which 
revealed that IFN-γ can induce IDO expression in several cell 
types and is produced by inflammatory cells in response to 
immune activation (36-38). This expression occurs during 
infectious, autoimmune and malignant diseases (2,3).
Although the majority of past research has focused on IDO 
as the central and immunobiologically relevant enzyme that 
catalyzes the conversion of tryptophan to Kyn, there are two 
additional enzymes, IDO-2 and tryptophan-2,3-dioxygenase 
(TDO), which can catalyze the same enzymatic reaction. 
TDO was first detected in the liver; however, little is known 
about the role of TDO in tumorigenesis or its association 
with IDO (39). IDO‑2 was recently identified and has slightly 
different expression pattern to IDO-1 (6). In the present study, 
the regulation of IDO-2 was examined in response to IFN-γ. 
Unstimulated BECs do not express IDO‑2; however, a signifi-
cant increase in IDO-2 expression was observed following 
treatment with IFN-γ.
TGF-β is an immunoregulatory cytokine produced by acti-
vated T cells that mediates its effect through TGF-β receptors 1 
and 2. A previous study demonstrated that CD8- DCs can induce 
IDO in response to TGF-β which can modify the cells from 
immunogenic into a tolerogenic state (40). Upon examination 
of the expression of TGF-β receptors 1 and 2, TGF-β receptor 
1 levels were not significantly altered, whereas TGF‑β receptor 
2 levels were significantly increased in response to IFN-γ. 
Furthermore, incubation of cells with the non-toxic pharma-
cological TGF-β receptor 1 inhibitor, SB-505124, followed by 
stimulation with IFN-γ had no effect on IDO-1 expression (data 
not shown). This suggests that, in BECs, the induction of IDO is 
IFN-γ-dependent, but independent of the TGF-β pathway.
The enzymatic activity of IDO was examined in H69 cells 
in the present study. Increased Kyn production and reduced 
substrate tryptophan demonstrated that IDO was enzymati-
cally functional in H69 cells. Additionally, significantly higher 
IDO activity was observed in sera derived from PBC patients 
compared with that from healthy controls. However, this 
Figure 2. Measurement of IDO enzymatic activity in immortalized biliary 
epithelial cell supernatants. Enzymatic activity was quantified by the colo-
rimetric assay for kynurenine, in the presence of IFN-γ (20 ng/ml) for 0 to 
120 h. IFN-γ, interferon-γ. The difference was significant (***P<0.05) between 
the supernatant of stimulated and unstimulated (control) cells.
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pathway is extremely responsive to non‑specific inflammation 
and is induced in all states of chronic inflammation, as IDO is 
an extremely sensitive IFN-γ responsive gene.
Liver sections from PBC patients were examined and it 
was confirmed that IDO is expressed in hepatocytes, as it is 
in other epithelial cells (41,42). Low-level expression of IDO 
was identified within BECs and strong expression was observed 
in hepatocytes, which indicates its potential role in PBC. Liver 
sections from matched patients with PBC expressed Foxp3. 
There was an increase in the number of inflammatory cells, 
particularly those exhibiting interface hepatitis and IDO expres-
sion. IDO was recognized in early stage PBC samples and 
within damaged cholangiocyte aggregates, identifying its role 
in immunogenicity and indicating its involvement in PBC (8).
The tryptophan metabolite 3‑HK significantly upregulated 
Foxp3 in human CD4+ T cells, thus polarizing the response 
towards a T-reg phenotype. In agreement with the data from 
the current study, prior research by Fallarino et al (21), found 
that tryptophan catabolites downregulate the expression of 
Figure 3. IDO enzymatic activity in human serum samples analyzed by HPLC. Kyn and tryptophan concentrations were measured by high-performance liquid 
chromatography in serum samples collected from 24 healthy donors and 47 PBC patients. The Mann Whitney unpaired t-test statistical analysis was used to 
compare the control and patient groups. (A) Kyn and tryptophan ratio (area under peak). (B) Kyn and tryptophan ratio (height of peaks). Kyn, kynurenine; 
Trypt, tryptophan; IDO, indoleamine 2,3-dioxygenase; PBC, primary biliary cirrhosis.
Figure 4. Expression of IDO and Foxp3 in PBC liver biopsies. The expres-
sion of IDO in liver tissues was examined in samples from healthy controls 
(n=5) and patients with PBC (n=5). (A) No IDO expression was observed 
in BECs of healthy controls. (B) Discrete IDO staining is observed in the 
BECs of patients with PBC. (C) IDO expression was markedly increased in 
periportal hepatocytes in conjunction with notable interface hepatitis. (D) A 
typical clustering of IDO positivity was observed in hepatocytes. Sections 
from matched PBC patients stained for Foxp3: (E) Foxp3 positive cells 
were detected and (F) infiltrating cells were positive for Foxp3. There is an 
increase in the number of inflammatory T‑reg cells, particularly with inter-
face hepatitis and IDO expression. Original images were captured at x100 
magnification. Arrows indicate the expression of IDO and Foxp3, respec-
tively. IDO, indoleamine 2,3-dioxygenase; PBC, primary biliary cirrhosis; 
BECs, biliary epithelial cells; Foxp3, forkhead box P3.
Figure 5. Foxp3 expression in human CD4+ T cells cultured with Kyns. CD4+ 
T cells were activated with anti-CD3/CD28 beads in the presence or absence 
of the indicated Kyns. At 5 days, cells were retrieved and the proportion of 
CD4+ T cells that were Foxp3‑positive was determined by intracellular flow 
cytometry. Results are representative of at least three independent experi-
ments. L-Kyn, kynurenine. CD, cluster of differentiation; Foxp3, forkhead 
box p3; 3-HK, 3-hydroxykynurenine; 3-HAA, 3-hydroxyanthranilic acid.
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T-cell receptor-ζ-chain and induce a regulatory phenotype in 
naïve T cells.
IDO activity is increased in autoimmune disorders and 
inflammation (43). In animal models of autoimmunity, such 
as that of experimental autoimmune encephalomyelitis 
(EAE), the presence of IDO-produced tryptophan metabo-
lites results in the skewing of a Th1 immune response 
towards a Th2 response, which results in reduced inflamma-
tion and tissue damage. Notably, a tryptophan metabolite, 
3,4,'-dimethoxycinnamoyl anthranilic acid, was able to 
reverse paralysis in mice with EAE (44). IDO immunosup-
pressive action serves as a negative feedback effect induced 
by hyper-activation of T-cell immunity. In the present study, 
although the Kyn/tryptophan ratio was increased in PBC 
patients, it is possible the level of IDO expression was not 
sufficient to produce the desired immunosuppression. This 
raises the possibility that Kyn metabolites could be used in 
disease resolution.
In conclusion, the present study demonstrated that expression 
of IDO in iBECs was stimulated by IFN-γ. The induction of IDO 
at the tissue level may serve a role in the pathogenesis of PBC. 
The effect of tryptophan metabolites on human CD4+ T cells in 
inducing polarization towards a T-reg phenotype suggests that 
there exists a therapeutic opportunity for the management of 
PBC. Furthermore, tryptophan catabolism could act as a poten-
tial biomarker to monitor disease progression in PBC.
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